Maria C Kjellsson

List of Publications by Year
in descending order

40 papers	593 citations	687363 13 h-index	642732 23 g-index
40 all docs	40 docs citations	40 times ranked	971 citing authors

#	Article	IF	Citations
1	Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions. Antimicrobial Agents and Chemotherapy, 2012, 56, 446-457.	3.2	154
2	Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach. Drug Metabolism and Disposition, 2016, 44, 505-516.	3.3	43
3	The effects of dose staggering on metabolic drug–drug interactions. European Journal of Pharmaceutical Sciences, 2003, 20, 223-232.	4.0	40
4	Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it. BMC Systems Biology, 2015, 9, 52.	3.0	40
5	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 2018, 57, 591-599.	3.5	26
6	The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 81-99.	1.8	22
7	Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes. Interface Focus, 2016, 6, 20150075.	3.0	21
8	Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. Journal of Pharmacokinetics and Pharmacodynamics, 2008, 35, 483-501.	1.8	19
9	A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment. Journal of Clinical Pharmacology, 2013, 53, 589-600.	2.0	19
10	Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED. Journal of Pharmacokinetics and Pharmacodynamics, 2004, 31, 299-320.	1.8	17
11	Model-Based Interspecies Scaling of Glucose Homeostasis. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 778-786.	2.5	17
12	Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 1-10.	1.8	16
13	Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart. Journal of Clinical Pharmacology, 2014, 54, 809-817.	2.0	15
14	Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats. AAPS Journal, 2016, 18, 1203-1212.	4.4	15
15	A Bounded Integer Model for Rating and Composite Scale Data. AAPS Journal, 2019, 21, 74.	4.4	15
16	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. Journal of Clinical Pharmacology, 2016, 56, 340-348.	2.0	14
17	Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models. Pharmaceutical Research, 2011, 28, 2610-2627.	3.5	12
18	Evaluation of the nonparametric estimation method in NONMEM VI. European Journal of Pharmaceutical Sciences, 2009, 37, 27-35.	4.0	9

#	Article	IF	Citations
19	Mathematical Modelling of Glucose–Dependent Insulinotropic Polypeptide and Glucagon–like Peptide–1 following Ingestion of Glucose. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 290-297.	2.5	8
20	The integrated glucose insulin minimal model: An improved version. European Journal of Pharmaceutical Sciences, 2019, 134, 7-19.	4.0	7
21	Model-Based Residual Post-Processing for Residual Model Identification. AAPS Journal, 2018, 20, 81.	4.4	6
22	Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations. Clinical Pharmacology and Therapeutics, 2020, 107, 238-245.	4.7	6
23	A Time–to–Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations. Clinical Pharmacology and Therapeutics, 2021, 109, 416-423.	4.7	6
24	Application of the integrated glucose–insulin model for cross–study characterization of T2DM patients on metformin background treatment. British Journal of Clinical Pharmacology, 2016, 82, 1613-1624.	2.4	5
25	Impact of demographics and disease progression on the relationship between glucose and HbA1c. European Journal of Pharmaceutical Sciences, 2017, 104, 417-423.	4.0	5
26	Study Design Selection in Early Clinical Anti–Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 432-441.	2.5	5
27	Using a semi–mechanistic model to identify the main sources of variability of metformin pharmacokinetics. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 105-114.	2.5	5
28	Sweet/Fat Preference Taste in Subjects Who are Lean, Obese and Very Obese. Pharmaceutical Research, 2020, 37, 244.	3.5	5
29	The back-step method—Method for obtaining unbiased population parameter estimates for ordered categorical data. AAPS Journal, 2004, 6, 13-22.	4.4	4
30	Good Penetration of Moxifloxacin into Human Abscesses. Pharmacology, 2012, 90, 146-150.	2.2	4
31	Semi–physiological model of postprandial triglyceride response in lean, obese and very obese individuals after a high–fat meal. Diabetes, Obesity and Metabolism, 2018, 20, 660-666.	4.4	3
32	Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 331-341.	2.5	2
33	Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data. AAPS Journal, 2021, 23, 9.	4.4	2
34	Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, Assessed with a Semimechanistic Model. Clinical Pharmacology and Therapeutics, 2022, 112, 112-124.	4.7	2
35	Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model–Based Analysis. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 686-694.	2.5	1
36	An Item Response Theory–Informed Strategy to Model Total Score Data from Composite Scales. AAPS Journal, 2021, 23, 45.	4.4	1

#	Article	IF	Citations
37	Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 815-823.	1.8	1
38	Postprandial triglyceride reduction following acute treatment of a selective 5‐hydroxytryptamine‐2c agonist and characterization using a semi‐physiological model. Diabetes, Obesity and Metabolism, 2021, 23, 1001-1010.	4.4	1
39	Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus. European Journal of Clinical Pharmacology, 2012, 68, 1419-1423.	1.9	0
40	Optimal Designs for Model‐Based Assessment of Insulin Sensitivity and Glucose Effectiveness. Journal of Clinical Pharmacology, 2021, 61, 116-124.	2.0	0